Cytotoxic T Lymphocyte–based Control of Simian Immunodeficiency Virus Replication in a Preclinical AIDS Vaccine Trial by Matano, Tetsuro et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2004/06/1709/10 $8.00
Volume 199, Number 12, June 21, 2004 1709–1718
http://www.jem.org/cgi/doi/10.1084/jem.20040432
 
1709
 
Cytotoxic T Lymphocyte–based Control of Simian 
Immunodeﬁciency Virus Replication in a Preclinical 
AIDS Vaccine Trial
 
Tetsuro Matano,
 
1,2 
 
Masahiro Kobayashi,
 
1 
 
Hiroko Igarashi,
 
1 
 
Akiko Takeda,
 
1,2 
 
Hiromi Nakamura,
 
2 
 
Munehide Kano,
 
2 
 
Chie Sugimoto,
 
2 
 
Kazuyasu Mori,
 
2 
 
Akihiro Iida,
 
3 
 
Takahiro Hirata,
 
3 
 
Mamoru Hasegawa,
 
3 
 
Takae Yuasa,
 
4 
 
Masaaki Miyazawa,
 
4 
 
Yumiko Takahashi,
 
5 
 
Michio Yasunami,
 
5 
 
Akinori Kimura,
 
5
 
David H. O’Connor,
 
6 
 
David I. Watkins,
 
6 
 
and Yoshiyuki Nagai
 
7
 
1
 
Department of Microbiology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan
 
2
 
AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan
 
3
 
DNAVEC Research Inc., Tsukuba 305-0856, Japan
 
4
 
Department of Immunology, Kinki University School of Medicine, Osaka 589-8511, Japan
 
5
 
Department of Molecular Pathogenesis, Division of Medical Science, Medical Research Institute, Tokyo Medical 
and Dental University, Tokyo 101-0062, Japan
 
6
 
Wisconsin Primate Research Center and Department of Pathology and Laboratory Medicine, University of Wisconsin, 
Madison, WI 53706
 
7
 
Toyama Institute of Health, Toyama 939-0363, Japan
 
Abstract
 
Recently, encouraging AIDS vaccine trials in macaques have implicated cytotoxic T lympho-
cytes (CTLs) in the control of the simian human immunodeficiency virus SHIV89.6P that
induces acute CD4
 
  
 
T cell depletion. However, none of these vaccine regimens have been
successful in the containment of replication of the pathogenic simian immunodeficiency viruses
(SIVs) that induce chronic disease progression. Indeed, it has remained unclear if vaccine-induced
CTL can control SIV replication. Here, we show evidence suggesting that vaccine-induced
CTLs control SIVmac239 replication in rhesus macaques. Eight macaques vaccinated with
DNA-prime/Gag-expressing Sendai virus vector boost were challenged intravenously with
SIVmac239. Five of the vaccinees controlled viral replication and had undetectable plasma
viremia after 5 wk of infection. CTLs from all of these five macaques rapidly selected for escape
mutations in Gag, indicating that vaccine-induced CTLs successfully contained replication of
the challenge virus. Interestingly, analysis of the escape variant selected in three vaccinees that
share a major histocompatibility complex class I haplotype revealed that the escape variant virus
was at a replicative disadvantage compared with SIVmac239. These findings suggested that the
vaccine-induced CTLs had “crippled” the challenge virus. Our results indicate that vaccine
induction of highly effective CTLs can result in the containment of replication of a highly
pathogenic immunodeficiency virus.
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Introduction
 
Virus-specific CD8
 
  
 
CTL responses are critical for the
control of immunodeficiency virus infections. The impor-
tance of CTLs in the control has been indicated by several
clinical correlations in HIV-1–infected humans (1–3) and
CD8
 
  
 
T cell depletion experiments in macaque AIDS
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models (4–6). Therefore, recent vaccine approaches have
focused on eliciting CTL responses (7, 8). However, HIV-
1–infected individuals often have high plasma virus con-
centrations despite the presence of high frequencies of
CTLs (9) and it has remained unclear if HIV-1 replication
can be contained by vaccine-elicited CTL responses.
DNA vaccines, recombinant viral vector–based vaccines,
and their combinations are promising delivery methods for
AIDS vaccine because of their potential for inducing CTL
responses. Recently, encouraging trials of these vaccines in
macaques have implicated vaccine-induced CTLs in the
control of the simian HIV (SHIV)89.6P that induces acute
CD4
 
  
 
T cell depletion (10–14). However, most of these
vaccine regimens used Env as an immunogen and it is
likely that Env-specific antibodies played a role in control
of this chimeric virus. Additionally, it has been suggested
that SHIV89.6P may not be an appropriate challenge virus
(15) and none of these vaccine regimens have been suc-
cessful in the containment of the more realistic challenge
of the pathogenic simian immunodeficiency viruses (SIVs)
smE660, mac251, or mac239 (16–19). Thus, it is quite im-
portant to know if vaccine induction of CTL responses can
lead to the containment of replication of these SIVs that in-
duce chronic disease progression.
We previously developed a DNA-prime/Gag-expressing
Sendai virus (SeV) vector boost vaccine system and showed
its potential for efficiently inducing Gag-specific cellular
immune responses (13, 20). In the preclinical trial, all the
vaccinated macaques controlled viremia and were pro-
tected from acute AIDS progression after SHIV challenge
(13, 21). In this study, we examined if CTL induction
by our vaccine system can result in the containment of
SIVmac239 replication.
 
Materials and Methods
 
Animals.
 
Male rhesus macaques (
 
Macaca mulatta
 
) originally
from southeastern Asia (Myanmar) were maintained in accor-
dance with the Guideline for Laboratory Animals of National In-
stitute of Infectious Diseases. These macaques were tested nega-
tive for SeV, SIV, and simian retrovirus type D before use. Blood
collection, vaccination, and virus challenge were performed un-
der ketamine anesthesia.
 
Vaccination and Challenge.
 
An 
 
env
 
- and 
 
nef
 
-deleted SHIV
DNA, SIVGP1, was constructed from an infectious SHIV
 
MD14YE
 
clone DNA as described previously (13, 22). The DNA is deleted
with a gene fragment encoding Env surface protein (SU; nucle-
otide [nt] 6211 to nt 7726 in HIV-1
 
DH12
 
; these sequence data
are available from GenBank/EMBL/DDBJ under accession no.
AF069140), the 3
 
  
 
portion of the 
 
env
 
 gene (nt 8628 to nt 8764 in
HIV-1
 
DH12
 
), and the 5
 
  
 
quarter of the 
 
nef
 
 gene (nt 9333 to nt
9481 in SIVmac239; GenBank/EMBL/DDBJ accession no.
M33262). From SIVGP1 DNA, the 5
 
  
 
long terminal repeat re-
gion was replaced with a CMV promoter with immediate early
enhancer and the 3
 
  
 
portion containing the remaining 
 
nef
 
 and the
3
 
  
 
long terminal repeat was replaced with Simian virus 40 poly
A to obtain CMV-SHIVdEN DNA. Therefore, the CMV-
SHIVdEN DNA has SIV-derived 
 
gag
 
, 
 
pol
 
, 
 
vif
 
, 
 
vpx
 
, and partial 
 
vpr
 
sequences and HIV-1–derived partial 
 
vpr
 
, 
 
tat
 
, 
 
rev
 
, and partial env
(nt 7726 to nt 8628 containing the second exon of 
 
tat
 
, the second
exon of 
 
rev
 
, and RRE) sequences. At DNA vaccination, animals
received 5 mg CMV-SHIVdEN DNA intramuscularly. We used
two kinds of SeV vectors, a transmissible one (SeV-Gag) and an
F-deleted nontransmissible one (F[
 
 
 
]SeV-Gag), for the boost.
Recombinant SeV-Gag and F(
 
 
 
)SeV-Gag were constructed and
recovered as described previously (20, 23, 24). 6 wk after the
DNA prime, animals received 10
 
8 
 
cell-infectious units of SeV-
Gag or 6 
 
  
 
10
 
9 
 
cell-infectious units of F(
 
 
 
)SeV-Gag intranasally
as a boost. Four macaques (V1, V2, V3, and V4) were vaccinated
with DNA-prime/SeV-Gag-boost, and the other four (V5, V6,
V7, and V8) were vaccinated with DNA-prime/F(
 
 
 
)SeV-Gag-
boost. 13 wk after the boost, animals were challenged intrave-
nously with 1,000 TCID
 
50 
 
(50% tissue culture–infective dose)
of SIVmac239 (25). An SIVmac239 molecular clone DNA,
pBRmac239, was provided by T. Kodama (University of Pitts-
burg, Pittsburgh, PA) and R.C. Desrosiers (New England Pri-
mate Research Center, Southborough, MA), and the virus obtained
from COS1 cells transfected with pBRmac239 was propagated
on rhesus macaque PBMCs to prepare the SIVmac239 challenge
stock.
 
Flow Cytometric Analysis of Virus-specific IFN-
 
  
 
Induction.
 
We
measured virus-specific T cell levels by flow cytometric analysis
of IFN-
 
  
 
induction after specific stimulation as described pre-
viously (13). In brief, PBMCs were cocultured with autolo-
gous herpesvirus papio-immortalized B lymphoblastoid cell lines
(B-LCLs; reference 26) infected with a vaccinia virus (Vv) vector
(27) for nonspecific Vv control stimulation and B-LCLs infected
with a Vv vector expressing SIVmac239 Gag for Gag-specific
Vv Gag stimulation, respectively. Intracellular IFN-
 
  
 
staining
was performed by using CytofixCytoperm kit (Becton Dickin-
son) according to the manufacturer’s instructions. FITC-conju-
gated anti–human CD4, peridinin chlorophyll protein–conjugated
anti–human CD8, allophycocyanin-conjugated anti–human CD3,
and anti–human PE-conjugated IFN-
 
  
 
antibodies (Becton Dick-
inson) were used. Gag-specific T cell levels were calculated by
subtracting the IFN-
 
 
 
  
 
T cell frequencies after nonspecific Vv
control stimulation from those after Gag-specific Vv Gag stimula-
tion. Alternatively, for measurement of SIV-specific T cell levels,
lymphocytes were cocultured with B-LCLs infected with a vesic-
ular stomatitis virus G (VSV-G)–pseudotyped murine leukemia
virus for nonspecific stimulation and B-LCLs infected with a
VSV-G–pseudotyped SIVGP1 for SIV-specific stimulation, re-
spectively. In the case of examining peptide-specific T cell levels,
B-LCLs were pulsed with each peptide (at a final concentration
of 1 
 
 
 
M) or peptide mixture (final concentration of each peptide
was 1–10 
 
 
 
M) for peptide-specific stimulation or incubated
without peptide for nonspecific stimulation. The peptides, in-
cluding a panel of 117 overlapping peptides (15–17 amino acids
[aa] in length and overlapping by 10 to 12 aa) spanning the entire
SIVmac239 Gag sequence, were purchased from Sigma Genosys
Japan. Specific T cell levels 
 
 
 
100 cells per million PBMCs were
considered negative, those between 100 and 200 borderline, and
those 
 
 
 
200 positive. Gag-specific T cells were undetectable be-
fore the vaccination in all of the vaccinees and before the chal-
lenge in all of the naive controls.
 
Quantitation of Plasma Viral Loads.
 
Plasma RNA was ex-
tracted using High Pure Viral RNA kit (Roche Diagnostics). For
quantitation of plasma SIV RNA levels, serial fivefold dilutions of
RNA samples were amplified in quadruplicate by RT and nested
PCR using SIV 
 
gag
 
-specific primers to determine the end point
as described previously (22). For preparing the RNA standard,
we first set up the method for quantitation of SHIV RNA copy 
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number by using HIV-1 
 
vpu
 
-specific primers and an HIV-1 stan-
dard quantitated by Amplicor HIV-1 Monitor (Roche Diagnos-
tics). By using this method, we prepared an SHIV standard for
the present assay. The lower limit of detection in this assay is
 
 
 
4 
 
  
 
10
 
2 
 
copies/ml. The plasma viral loads at several time points
were confirmed by real time PCR (28).
 
Sequencing.
 
Plasma RNA was extracted using High Pure Vi-
ral RNA kit or RNA extraction system in Amplicor HIV-1
Monitor. The fragment spanning from nt 1231 to nt 2958 in
SIVmac239 containing all of the 
 
gag
 
 region was amplified from
plasma RNA by nested RT-PCR. In case of the plasma with low
viral loads (
 
 
 
2,000 copies/ml), 8–16 tubes of nested RT-PCR
amplifications were performed for each plasma to avoid obtain-
ing only unrepresentative clones. The PCR products were se-
quenced using dye terminator chemistry and an automated DNA
sequencer (Applied Biosystems). Alternatively, the PCR products
were subcloned into a plasmid DNA by using the TOPO cloning
system (Invitrogen) and sequenced.
 
Isolation of Mamu-A/B cDNA Clones.
 
Total cellular RNA
was used to synthesize oligo(dT)-primed cDNA with reverse
transcriptase (Superscript II; Invitrogen). Full-length cDNAs of
 
Mamu-A
 
 and 
 
Mamu-B
 
 were amplified by PCR with locus-specific
primer pairs (
 
Mamu-A
 
 forward: 5
 
 
 
-ATGGCGCCCCGAACCC-
TCCTCCTG-3
 
 
 
, 
 
Mamu-A
 
 reverse: 5
 
 
 
-TCACACTTTACAAG-
CCGTGAGAGA-3
 
 
 
; 
 
Mamu-B
 
 forward: 5
 
 
 
-ATGGCGCCCC-
GAACCCTCCTCCTG-3
 
 
 
, 
 
Mamu-B
 
 reverse: 5
 
 
 
-TCAAGCC-
GTGAGAGACACATC-3
 
 
 
) and cloned in pGEM-T Easy vector
(Promega). The integrity of the clones was verified by reference
strand–mediated conformation analysis (RSCA; 29) as the fol-
lowing and then sequenced.
 
Determination of Mamu MHC-I Haplotype.
 
Locus-specific
RT-PCR products were subjected to second round PCR to
obtain 725-bp-long DNA fragments encoding Mamu-A/B
extracellular domains using 
 
Mamu-A/B
 
 universal forward (5A:
5
 
 
 
-ATGGCGCCCCGAACCCTC-3
 
 
 
) and reverse (4R: 5
 
 
 
-
CCAGGTCAGTGTGATCTCCG-3
 
 
 
) primers. The product
was analyzed by RSCA conformation analysis essentially as de-
scribed previously (31). In brief, the second round PCR products
and “a reference strand,” a fragment derived from the same PCR
condition except for using 5
 
  
 
Cy5-labeled forward primer and a
certain cloned DNA template (its sequence is available upon re-
quest), were mixed together in a reaction tube, heat denatured,
and then cooled down to form heteroduplex DNA. The mobility
of heteroduplex DNA molecules in 6% nondenaturing Long
Ranger gel (BioWhittaker Molecular Applications) was measured
by ALF express II automated sequencing apparatus (Amersham
Biosciences). Fluorescence electropherograms showed multiple
peak patterns corresponding to multiple, different kinds of se-
quences expressed in individual macaques. The identity of each
peak was determined by comparison of its mobility with those of
heteroduplexes derived from parallel PCR using 
 
Mamu-A/B
 
cDNA clones as templates. Alleles that were shared by a breeder
macaque and subset of his sons were thought to be transmitted
together and assigned to a single haplotype. The number of ex-
pressed alleles on one MHC-I haplotype ranged from one 
 
A
 
 and
two 
 
B
 
 alleles to no less than three 
 
A
 
 and five 
 
B
 
 alleles.
 
Typing of MHC-II (Mamu-DRB and Mamu-DQA).
 
MHC-II
alleles and haplotype compositions of macaques were analyzed by
sequencing of cloned cDNA and denaturing gradient gel electro-
phoresis (DGGE; reference 30). Total RNA was extracted from
B-LCLs and cDNA was generated by using SuperScript II reverse
transcriptase. The entire DRB cDNA and the DQA exon 2 frag-
ments were amplified by PCR using the following primer sets de-
signed to hybridize with the conserved monomorphic regions: 5
 
 
 
-
CGCGAATTCTCAGCTCAGGAGTCC-3
 
  
 
and 5
 
 
 
-GCGG-
GATCCATGGTGTGTCTG-3  for DRB, and 5 -CGCGAAT-
TCGGTAGCAGCGGTAGAGT-3  and 5 -GCGGGATCCGT-
GTAAACTTGTACCAGTT-3   for DQA. The PCR products
were subcloned into pUC19 and sequenced. When more than four
clones with an identical sequence were obtained for an allele, the
allele was considered to be expressed in the animal (see Table I).
The number of DRB alleles expressed in macaques and their
haplotype relationships were analyzed by comparing the patterns
of DGGE and by cloning and sequencing of the DNA extracted
from each band in the gel. For DGGE analyses, the DRB exon 2
fragment was amplified by PCR using the forward (5 -CACTG-
GCTTTGGCTGGGGACAC-3 ) and the GC-clamped reverse
(5 -CGCCCGCCGCGCCCCGCGCCCGGCCCGCCGCCGC-
CCCCGCCCGCAGGATACACAGTCACCTTAG-3 ) prim-
ers. DGGE was performed in 6% polyacrylamide gel containing a
gradient of 36–50% of the denaturant mixture (7 M urea and 40%
formamide) at 100 V at 60 C for 2.5 h in a DCode system (Bio-
Rad Laboratories). DNA eluted from each separate band was
subcloned into a plasmid by using the TOPO cloning system and
sequenced.
Figure 1. Gag-specific T cell frequencies in vaccinated macaques.
Macaques V1, V2, V3, and V4 were boosted with a replication-competent
SeV-Gag, whereas macaques V5, V6, V7, and V8 were boosted with a
replication-defective F( )SeV-Gag. *, macaques that controlled SIV rep-
lication after challenge. (A) Gag-specific CD8  T cell frequencies per million
PBMCs. The frequencies at week 7 after vaccination (1 wk after boost),
at week 8 after vaccination (2 wk after boost), at week 19 after vaccination
(just before challenge), and at week 2 after challenge (2 wk after challenge)
are shown. (B) Gag-specific CD4  T cell frequencies per million PBMCs
at week 7 after vaccination (1 wk after boost). The frequencies were
calculated by subtracting the IFN-   T cell frequencies after nonspecific
Vv control stimulation from those after Gag-specific Vv Gag stimulation.
The background IFN-   T cell frequencies after nonspecific stimulation
were  2.0   102.Vaccine-induced CTL-based Control of SIV Replication 1712
Results
Gag-specific T Cell Induction after SeV-Gag-Boost. Our
extremely simple vaccine protocol consisted of a single
prime with DNA followed by a single boost with a recom-
binant SeV vector expressing SIVmac239 Gag 6 wk after
the prime. Eight rhesus macaques (V1, V2, V3, V4, V5,
V6, V7, and V8) were vaccinated with the prime/boost,
and four naive controls (N1, N2, N3, and N4) received no
vaccination before an intravenous SIVmac239 challenge.
We measured virus-specific T cell levels in the vacci-
nated macaques by flow cytometric detection of antigen-
specific IFN-  induction. SIV- and Gag-specific T cell re-
sponses were examined in PBMCs at weeks 2 and 6 after
the DNA vaccination, respectively, but no responses to ei-
ther SIV or Gag were detectable in any of the vaccinated
macaques (not depicted). After the SeV boost, however,
we found induction of Gag-specific CD8  T cells in all of
the vaccinees (Fig. 1 A). The levels differed among the
macaques, with five (V1, V2, V3, V4, and V5) maintaining
detectable levels of Gag-specific CD8  T cells until chal-
lenge. The SeV boost also induced Gag-specific CD4  T
cells in all eight vaccinees (Fig. 1 B).
Control of SIVmac239 Replication in Five of Eight Vaccinees.
These vaccinated macaques were challenged intravenously
with 1,000 TCID50 of SIVmac239 at week 19 after the
DNA prime (13 wk after the SeV boost). The unvacci-
nated control macaques had high peak viremia ( 107
SIV RNA copies/ml plasma) on day 10 after challenge
and maintained relatively high plasma viral concentrations
(104–106 SIV RNA copies/ml plasma; Fig. 2). Three of
them showed gradual loss of percent CD4 in peripheral T
lymphocytes. In contrast, five vaccinated macaques (V3,
V4, V5, V6, and V8) controlled replication of this highly
pathogenic challenge virus. In these macaques, plasma
viremia became undetectable after week 5 and peripheral
CD4  T cells were maintained. The other three vaccinees
(V1, V2, and V7) failed to control virus replication and
Figure 2. Changes in peripheral
CD4  T cell levels and plasma viral
loads after SIVmac239 challenge.
(A) Percents of CD4  T cells in pe-
ripheral blood. (B) CD4   T cell
counts in peripheral blood. (C) Plasma
viral loads (SIV RNA copy number/
ml). The left panels show the naive
controls (N1, N2, N3, and N4), the
middle panels show the vaccinees
that failed to control SIV replication
(V1, V2, and V7), and the right panels
show the vaccinees that controlled
SIV replication (V3, V4, V5, V6,
and V8). The portion until week 10
after challenge is enlarged.Matano et al. 1713
showed gradual loss of percent CD4 in peripheral T lym-
phocytes similar to the naive control animals. One of
them (macaque V2) was killed at week 42 because of dys-
pnea, loss of body weight, and loss of peripheral CD4  T
cells (4.4%, 97 cells/ l at week 42). Autopsy revealed
that this animal developed AIDS with Pneumocystis carinii
pneumonia.
At week 2 after challenge, we detected anamnestic
Gag-specific CD8  T cell responses in all of the vacci-
nated macaques, indicating efficient secondary responses
during the acute phase of infection (Fig. 1 A). These levels
varied from macaque to macaque. Macaque V5 showed
the highest level of Gag-specific CD8  T cells and ma-
caque V7 showed the lowest. No significant difference
in the levels was observed between the macaques that
controlled viral replication and those that did not. The
magnitude of the total prechallenge Gag-specific CD8  T
cell or CD4  T cell responses did not appear to correlate
with the level of control. We examined plasma-neutraliz-
ing activities against SIVmac239 as described previously
(31), but found no neutralizing activities in any of the
controls or the vaccinees at weeks 5 or 12 after challenge
(not depicted), indicating that neutralizing antibodies
were not essential for the control of SIV replication ob-
served in this experiment.
Rapid Selection of CTL Escape Variants in the Vacci-
nees That Controlled SIVmac239 Replication. To determine
whether vaccine-induced Gag-specific T cell responses ex-
erted a selective pressure on the virus, we sequenced the
SIV gag region in the viral genomes obtained from plasma
RNA at week 5 after challenge (Fig. 3 A). The numbers of
aa changes per clone in the vaccinated macaques were sig-
nificantly higher than those in the unvaccinated (mean: un-
vaccinated, 0.51; vaccinated, 1.75; P   0.0006 by t test).
This may reflect the immune pressure by vaccine-induced
Gag-specific T cell responses. Interestingly, all of the
macaques that controlled SIVmac239 replication (V3, V4,
V5, V6, and V8), but not those unable to control the virus,
showed consistent aa changes in Gag (Fig. 3 A). Among
them, three macaques (V3, V4, and V5) had a common aa
change, leucine (L) to serine (S) at the 216th aa in Gag. We
then examined peptide-specific T cell responses after the
SeV boost and found, in these three macaques but not in
the other vaccinees, efficient expansion of CD8  T cells
specific for an epitope (Gag206–216; IINEEAADWDL) span-
ning from the 206th to the 216th aa in SIVmac239 Gag.
Interestingly, these three macaques showed no or dimin-
ished recognition of the mutant peptide, IINEEAADWDS
(Gag206–216L216S; Fig. 4 A), indicating that this mutant
likely represents an escape variant. Sequence analysis of vi-
Figure 3. Mutations in SIV gag. (A) Schematic
representation of the positions of aa changes in
SIV Gag in each macaque after challenge. 6–10
clones of plasmids carrying the whole gag region
amplified from plasma RNA at week 5 after
challenge were obtained from each macaque
and sequenced. Each lane represents the whole
gag sequence derived from each clone and the
positions of aa changes detected are indicated.
Total number of aa changes and number of
clones sequenced are shown in the parentheses.
All the changes at aa 58 were glutamine to
lysine, and all at aa 377 were isoleucine to thre-
onine. All the changes at aa 216 other than the
one indicated as 216P were L to S. The 216P
represents L to P change at aa 216. (B) Fre-
quencies of the CTL escape mutants at weeks 2,
3, and 5 in the vaccinees that controlled SIV
replication. The ratio of the number of the
clones with the escape mutation to the number
of the sequenced clones is shown.Vaccine-induced CTL-based Control of SIV Replication 1714
ral genomes from the three macaques that made responses
to this epitope at weeks 2 and 3 revealed that this CTL es-
cape mutant became dominant around week 3 after chal-
lenge (Fig. 3 B). Thus, in these three macaques with high
levels of Gag206–216-specific CD8  T cells, the wild-type
challenge virus disappeared quickly and only the CTL es-
cape mutant was detectable in plasma at week 5. These
three macaques had high levels of Gag206–216-specific CD8 
T cells 3 wk after challenge. However, these levels were
considerably reduced in the chronic phase (Fig. 4 B).
We further examined epitope-specific CD8  T cell re-
sponses in the other two macaques that controlled viral rep-
lication. In macaque V6, a mutation leading to a change at
the 377th aa (isoleucine to threonine) was observed at week
5 (Fig. 3 A). Analysis of peptide-specific responses revealed
that this macaque had a high level of CD8  T cells specific
for a 15-mer peptide corresponding to aa 367–381 in
SIVmac239 Gag (Gag367–381) at week 3 after challenge.
Stimulation by the mutant Gag367–381 peptide with the sub-
stitution (Gag367–381I377T) induced IFN-   CD8  T cells,
but their frequency was lower than that after stimulation by
the wild-type Gag367–381 peptide (Fig. 4 A). Additionally, vi-
ruses from macaque V8 had a mutation leading to a change
at the 58th aa (glutamine to lysine; Fig. 3 A). In this animal,
CD8  T cell responses specific for a 16-mer peptide corre-
sponding to aa 50–65 in SIVmac239 Gag (Gag50–65) were
observed at week 3 after challenge. Stimulation by the mu-
tant Gag50–65 peptide with the substitution (Gag50–65Q58K)
failed to induce IFN-   CD8  T cells (Fig. 4 A). Each of
these mutants became dominant at approximately week 5
after challenge in the corresponding macaque (Fig. 3 B).
Among the 12 macaques used in the challenge experi-
ment, 8 macaques (2 naive controls and 6 vaccinees) de-
scended from a single male, macaque R90-120 (its sons:
N2, V2, and V3; its grandsons: N3, V4, V5, V6, and V7;
Table I). Analysis of MHC-I Mamu-A and Mamu-B alleles
indicated that four macaques of the eight R90-120 descen-
dants, N2, V3, V4, and V5, share an MHC-I haplotype
(90–120-Ia) derived from macaque R90-120. Analysis of
MHC-II also suggested that these macaques possibly share
an MHC-II haplotype derived from macaque R90-120.
Among these macaques possessing the 90–120-Ia haplo-
type, three (V3, V4, and V5) were vaccinees that con-
trolled SIV replication with high levels of Gag206–216-spe-
Figure 4. Peptide-specific T cell frequencies in the vaccinees that con-
trolled SIV replications. (A) Comparison between the epitope peptide–
specific and the variant peptide–specific CD8  T cell responses. PBMCs
at week 10 after vaccination in macaque V3, at week 10 after vaccination
in V4, at week 15 after vaccination in V5, at week 3 after challenge in
V6, and at week 3 after challenge in V8 were used. The open bars indi-
cate the levels of CD8  T cells specific for Gag206–216 peptide in V3, V4,
and V5, Gag367–381 peptide in V6, and Gag50–65 peptide in V8, respec-
tively. The solid bars indicate the levels of CD8  T cells specific for
Gag206–216L216S peptide in V3, V4, and V5, Gag367–381I377T peptide in
V6, and Gag50–65Q58K peptide in V8, respectively. (B) Gag206–216-specific
CD8  T cell levels in macaques V3, V4, and V5 after challenge. The
background IFN-   CD8  T cell frequencies after nonspecific stimula-
tion were  1.0   102.
Figure 5. Comparison of replication efficiencies between the wild-type
SIVmac239 and the escape variant SIVmac239G216S. (A) Replication
kinetics of SIVmac239 ( ) and SIVmac239G216S ( ) in macaque PBMCs.
MT4 cells were transfected with pBRmac239 and pBRmac239G216S to
obtain SIVmac239 and SIVmac239G216S, respectively. PBMCs were
infected with the viruses at a multiplicity of infection of 0.0002 and con-
centrations of SIV Gag p27 in their culture supernatants were measured
by ELISA (Beckman Coulter). A representative result from three inde-
pendent experiments is shown. (B) Plasma viral loads (SIV RNA copy
number/ml) in macaques M1 ( ) and M2 ( ) after inoculation with
both of the wild-type SIVmac239 molecular clone DNA and the mutant
SIVmac239G216S molecular clone DNA. (C) Frequencies of the mu-
tant viral genome in plasma in the macaques inoculated with both of
the wild-type SIVmac239 molecular clone DNA and the mutant
SIVmac239G216S molecular clone DNA. In case of direct sequencing of
the PCR products (indicated by direct),    indicates detection of both
the wild-type and the mutant at comparable levels,   indicates detection
of the wild-type predominantly and the mutant slightly, and   indicates
detection of the wild-type only. In case of sequencing clones (indicated
by clones), the ratio of the number of the mutant clones to the number of
the sequenced clones is shown.Matano et al. 1715
cific CD8  T cell responses. The remaining one (naive
control macaque N2) showed a detectable level of Gag206–216-
specific CD8  T cell responses at week 3 after challenge,
although the level was low (2.5    102 cells/million
PBMCs). These results strongly suggest that the Gag206–216
epitope is restricted by an MHC-I molecule derived from
the 90–120-Ia haplotype.
Diminished Replicative Ability of the CTL Escape Variant
SIV. We then explored the hypothesis that the escape
mutation selected by the vaccine-induced Gag206–216-spe-
Table I. MHC-I and MHC-II Alleles of Macaques Used in This Study
Animala Father
MHC-I
Mamu-A & B
RSCA patternb
MHC-II
Mamu-DRB & DQA allelesc
Naive control
N1 R90-088 *1 DRB1(Z26148), DRB*W502, DQA1*03(M76230)
DRB(AB112040), DRB*W2603, DRB*W402, DQA1*0502
N2 R90-120 90-120-Ia DRB1*1007, DRB1(Z26137), DQA1*03(M76228)
DRB(Z26165), DRB(AB112039), DRB(AB112043), DQA1*06(MM76195)
N3 R94-027d *2 DRB1*0316, DRB*W2507, DQA1*01(M76202)
DRB*W2104, DRB*W2603, DRB*W606, DQA1*0502
N4 R90-010 ND DRB*W2104, DRB*W2603, DQA1*0502
DRB*0321, DRB*0323, DRB*W606, DQA1*05(M76227)
Vaccinee
V1 R90-088 *1 DRB1(Z26148), DRB*W502, DQA1*03(M76230)
DRB*W2505, DRB(AB112046), DRB(AB124813), DQA(AB124814)
V2 R20-120 90-120-Ib DRB*W2002, DRB*W2501, DQA1*0502
DRB1(Z26148), DRB*W502, DQA1*03(M76230)
V3 R90-120 90-120-Ia DRB1*1007, DRB1(Z26137), DQA1*03(M76228)
DRB1(Z26148), DRB*W502, DQA1*03(M76230)
V4 R94-027 90-120-Ia DRB1*1007, DRB1(Z26137), DQA1*03(M76228)
DRB*W2505, DRB(AB112046), DRB(AB124813), DQA(AB124814)
V5 R94-027 90-120-Ia DRB1*1007, DRB1(Z26137), DQA1*03(M76228)
DRB(AB112043), DRB(AB112047)
V6 R94-027 *2 DRB1*0316, DRB*W2507, DQA1*01(M76202)
DRB1(Z26148), DRB*W502, DQA1*03(M76230)
V7 R94-027 *2 DRB1*0316, DRB*W2507, DQA1*01(M76202)
DRB*W2104, DRB*W2603, DRB*W606, DQA1*0502
V8 R90-010 ND DRB*W2104, DRB*W2603, DQA1*0502
DRB1*0316, DRB*W2507, DQA1*09(M76200)
Breeder
R90-088 unknown *1 DRB1(Z26148), DRB*W502, DQA1*03(M76230)
R90-120 unknown 90-120-Ia DRB1*1007, DRB1(Z26137), DQA1*03(M76228)
90-120-Ib DRB*W2002, DRB*W2501, DQA1*0502
R90-010 unknown ND DRB*W2104, DRB*W2603, DQA1*0502
DRB1*0316, DRB*2507, DQA1*01(M76202)
aThe underlined macaques showed control of SIV replication.
bMHC-I Mamu-A and Mamu-B alleles and haplotype compositions of macaques were examined by RSCA and sequencing of cloned cDNA. The
haplotype 90-120-Ia derived from macaque R90-120 consists of three Mamu-A alleles (Mamu-A120-1, Mamu-A120-4, and Mamu-A120-5) and four
Mamu-B alleles (Mamu-B120-1, Mamu-B120-6, Mamu-B120-8, and Mamu-B120-9). The haplotype 90-120-Ib derived from macaque R90-120
consists of two Mamu-A alleles (Mamu-A120-2 and Mamu-A120-3 [  Mamu-A*05]) and five Mamu-B alleles (Mamu-B120-2, Mamu-B120-3, Mamu-
B120-4, Mamu-B120-5 [  Mamu-B*36], and Mamu-B120-7). Macaques N1 and V1 shared an RSCA pattern of a haplotype derived from R90-088
(*1). Macaques N3, V6, and V7 shared an RSCA pattern of a haplotype not derived from R90-120 (*2).
cMHC-II Mamu-DRB and Mamu-DQA alleles were analyzed by DGGE and sequencing of cDNA. The determined alleles are shown. Each number
in parentheses indicates the corresponding accession number for the nt sequence of the allele that has not yet been designated.
dThe father of macaque R94-027 is macaque R90-120.Vaccine-induced CTL-based Control of SIV Replication 1716
cific CTL resulted in a loss of viral fitness. We constructed
a molecular clone of the escape mutant SIV, referred to as
SIVmac239G216S, with a mutation resulting in the L to S
substitution at the 216th aa in Gag. The mutant SIV was
replication competent in vitro but showed lower levels of
proliferation kinetics in PBMC culture compared with
the wild-type SIVmac239 (Fig. 5 A). To compare the
SIVmac239G216S replication kinetics with the wild-type
in macaques, two macaques (M1 and M2, neither of them
descended from macaque R90-120) were coinoculated in-
tramuscularly with 5 mg of the SIVmac239 molecular clone
DNA (pBRmac239) and 5 mg of the SIVmac239G216S
molecular clone DNA (pBRmac239G216S; Fig. 5, B and
C). Both viral genomes were detected at comparable levels
in plasma from both of the macaques at week 1 after the in-
oculation. After that, however, the mutant SIVmac239G216S
disappeared and the wild-type SIVmac239 became domi-
nant. Neither of the macaques showed Gag206–216-spe-
cific CD8  T cell responses at week 3 (not depicted).
These results indicate that the L to S change at the 216th
aa in Gag is disadvantageous for SIV replication in the ab-
sence of Gag206–216-specific CD8   T cell responses in
macaques.
Discussion
In this study, we present evidence indicating that vac-
cine-induced CTLs control SIVmac239 replication in rhe-
sus macaques. Each of the macaques that controlled viral
replication had a mutation in Gag leading to an aa change
in a CTL epitope by week 5 after challenge, reflecting
strong CTL-induced selective pressure. This finding lends
support to the notion that epitope-specific CTL responses
played a central role in the control of replication of the
SIVmac239 challenge virus because it was difficult to detect
the challenge virus at week 5 after challenge.
Among the 12 macaques used in the challenge experi-
ment, 8 macaques descended from macaque R90-120 and
4 of them shared an MHC-I haplotype, 90–120-Ia. Among
the four, not the naive (N2) but the three vaccinees (V3,
V4, and V5) controlled SIV replication and selected for the
same Gag206–216-specific CTL escape variant with L to S
change at the 216th aa in Gag. Therefore, we examined the
reproducibly selected escape variant SIVmac239G216S in-
tensively and found that in the absence of Gag206–216-spe-
cific CD8  T cell responses, its replication efficiency is di-
minished compared with the wild-type SIVmac239 in vivo
as well as in vitro. The rapid selection of the escape variant
with lower viral fitness in the vaccinees with Gag206–216-
specific CTLs indicates that the vaccine-induced CTLs ex-
erted strong immune pressure leading to clearance of the
wild-type SIVmac239.
The emergence of escape variants depends on the bal-
ance between CTL-induced immune pressure and viral fit-
ness costs (32). Viral escape from CTLs during the acute
phase of natural immunodeficiency virus infections has
been observed in Tat, Nef, Vpr, and Env (33–36). Escape
variants with mutations in the structural protein Gag have
been also reported (37), but it has been shown that they
mostly diminish viral fitness and require multiple additional
compensatory mutations to restore their replicative compe-
tence (38–41). Indeed, the Gag206–216-specific CTL escape
variant selected in macaques V3, V4, and V5 diminished
viral replication. Therefore, our results suggest that the vac-
cine-induced CTLs were crucial to the rapid containment
of replication of the challenge virus and selected for the vi-
rus with diminished replicative ability. Without compensa-
tory mutations, the crippled virus might be easily con-
trolled by the immune system.
The macaques used in our challenge experiment were
non-Indian rhesus and the setpoint plasma viral loads in the
naive control group might be lower than those usually ob-
served in SIVmac239-infected Indian rhesus. However, the
viral loads are higher than those typically observed in un-
treated humans infected with HIV-1 and equivalent to vi-
ral loads seen in SIVsmE660-infected Indian rhesus (16,
42). Indeed, all of the naive animals failed to control the vi-
rus replication after SIVmac239 challenge, indicating that
CTLs are unable to contain and clear the virus in natural
SIVmac239 infections of our non-Indian rhesus macaques.
Thus, this study provides clear evidence demonstrating that
vaccine induction of effective CTLs that can cripple the vi-
rus can result in the containment of replication of a neutral-
ization-resistant, highly pathogenic immunodeficiency vi-
rus that is unable to be contained in the natural chronic
course of infections. In conclusion, our results show that
vaccine-induced CTLs can control SIVmac239 replication
and indicate that induction of highly effective CTLs might
be critical for the vaccine-based containment of immuno-
deficiency virus replication.
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